Trials / Terminated
TerminatedNCT00577356
Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer
Phase II Trial of Neoadjuvant Docetaxel and CG1940/CG8711 Followed by Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Benaroya Research Institute · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out what effects, good and bad, the combination of docetaxel with CG1940/CG8711 (immunotherapy drugs) have on destroying prostate cancer before removal the prostate (prostatectomy).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel | Docetaxel 75mg/m2 will be given intravenously every 3 weeks for four cycles. |
| BIOLOGICAL | CG1940/CG8711 | Immunotherapy allogeneic GM-CSF secreting cellular vaccine |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2008-09-01
- Completion
- 2008-09-01
- First posted
- 2007-12-20
- Last updated
- 2011-01-20
- Results posted
- 2011-01-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00577356. Inclusion in this directory is not an endorsement.